Lung microbiome in idiopathic chronic fibrosing interstitial pneumonia

Lung microbiome in idiopathic chronic fibrosing interstitial pneumonia - Lung microbiome in idiopathic chronic fibrosing interstitial pneumonia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036868

Enrollment

Registered

2019-05-29

Start date

2019-05-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic chronic fibrosing interstitial pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed with idiopathic chronic fibrosing interstitial pneuonia according to ATS/ERS/JRS/ALAT IPF guideline 2018 and/or ATS/ERS IIP statement 2013 2. No lung infection and acute exacerbation within 3 months 3. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Concomitant malignancy (eligible if cured) 2. Impossible to undergo pulmonary function tests 3. On long-term oxygen therapy (eligible ambulatory oxygen only)

Design outcomes

Primary

Measure	Time frame
Relationship between lung microbiome and time to respiratory hospitalization.	—

Secondary

Measure	Time frame
1. Relationship between lung microbiome and time to progression. 2. Characteristics of lung microbiome in patients with idiopathic chronic fibrosing interstitial pneumonia. 3. Relationship between lung microbiome and FVC % predicted. 4. Relationship between lung microbiome and PaO2. 5. Relationship between lung microbiome and KL-6. 6. Relationship between lung microbiome and decrease in FVC % predicted. 7. Relationship between lung microbiome and time to acute exacerbation. 8. Relationship between lung microbiome and causal microbe in patients who are hospitalized due to pneumonia or bronchitis. 9. Relationship between lung microbiome and time to death. 10. Characteristics of lung microbiome at acute exacerbation. 11. Relationship between lung microbiome and cytokines in BALF. 12. Relationship between cytokines in BALF and FVC % predicted, PaO2, KL-6, time to progression, time to respiratory hospitalization, time to acute exacerbation, and time to death.	—

Measure

Time frame

1. Relationship between lung microbiome and time to progression. 2. Characteristics of lung microbiome in patients with idiopathic chronic fibrosing interstitial pneumonia. 3. Relationship between lung microbiome and FVC % predicted. 4. Relationship between lung microbiome and PaO2. 5. Relationship between lung microbiome and KL-6. 6. Relationship between lung microbiome and decrease in FVC % predicted. 7. Relationship between lung microbiome and time to acute exacerbation. 8. Relationship between lung microbiome and causal microbe in patients who are hospitalized due to pneumonia or bronchitis. 9. Relationship between lung microbiome and time to death. 10. Characteristics of lung microbiome at acute exacerbation. 11. Relationship between lung microbiome and cytokines in BALF. 12. Relationship between cytokines in BALF and FVC % predicted, PaO2, KL-6, time to progression, time to respiratory hospitalization, time to acute exacerbation, and time to death.

—

Countries

Japan

Contacts

Public ContactOsamu Nishiyama

Kindai University, Faculty of Medicine Department of Respiratory Medicine and Allergology

nishi-o@med.kindai.ac.jp072-366-0221

Outcome results